• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
Generic Name: Phosphorodiamidate morpholino oligomer (5¿- CTATATATAGTTATTCAACA -3¿)
Date Designated: 03/04/2020
Orphan Designation: Treatment of Spinal Muscular Atrophy
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Shift Pharmaceuticals Holdings, Inc.
8318 West 102nd Street
Overland Park, Kansas 66212
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.